Interaction study between remoxipride and biperiden.
Twelve healthy male volunteers took part in a double-blind randomised cross-over study composed of three treatment sessions: remoxipride 100 mg; remoxipride 100 mg plus biperiden 4 mg; and biperiden 4 mg. Plasma and urine concentrations of remoxipride and biperiden, plasma prolactin levels, salivary flow and adverse events were recorded to assess pharmacodynamic interactions. Remoxipride and biperiden had no effect on each other's plasma concentrations. Biperiden did not affect the urinary recovery or renal clearance of remoxipride. Prolactin levels were unaffected by biperiden but increased following remoxipride administration. Differences in prolactin Cmax and tmax following remoxipride versus concomitant (remoxipride + biperiden) treatment were not statistically significant. However, a slight but statistically significant (P = 0.04) increase in prolactin AUC was observed after concomitant treatment. No significant differences could be observed between the recorded salivary flow in all the treatment sessions. Single doses of remoxipride and biperiden showed no pharmacokinetic or pharmacodynamic interaction.
Yisak
W
W
Department of Clinical Pharmacology, Astra Arcus AB, Södertälje, Sweden.
Farde
L
L
von Bahr
C
C
Nilsson
L B
LB
Fredriksson
G
G
Ogenstad
S
S
D000328:Adult; D001712:Biperiden / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002852:Chromatography, Ion Exchange; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D008297:Male; D011388:Prolactin / Q000097:blood; D017330:Remoxipride / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D012472:Salivation / Q000187:drug effects; D013056:Spectrophotometry, Ultraviolet
D017330:Remoxipride; D001712:Biperiden; D011388:Prolactin